Vaccine candidates for HIV-1 so far have not been able to elicit broadly neutralizing antibodies (bNAbs) although they express the epitopes recognized by bNAbs to the HIV envelope glycoprotein (Env). To understand whether and how Env immunogens interact with the predicted germline versions of known bNAbs, we screened a large panel (N:56) of recombinant Envs (from clades A, B and C) for binding to the germline predecessors of the broadly neutralizing anti-CD4 binding site antibodies b12, NIH45-46 and 3BNC60. Although the mature antibodies reacted with diverse Envs, the corresponding germline antibodies did not display Env-reactivity. Experiments conducted with engineered chimeric antibodies combining the mature and germline heavy and light c...
The CD4 binding site (CD4bs) of the HIV-1 envelope glycoprotein is susceptible to multiple lineages ...
SummaryBroadly neutralizing antibodies (bnAbs) against the N332 supersite of the HIV envelope (Env) ...
Worldwide, over 37 million people are currently infected with rapidly mutating human immunodeficienc...
Vaccine candidates for HIV-1 so far have not been able to elicit broadly neutralizing antibodies (bN...
Broadly neutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV)-1 are rare in nat...
Broadly neutralizing antibodies (bnAbs) against HIV are believed to be a critical component of the p...
Several human monoclonal antibodies (hmAbs) and antibody fragments, including the best characterized...
HIV-1 envelope glycoproteins (Env) and Env-based immunogens usually do not interact efficiently with...
Efforts to elicit broadly neutralizing antibodies (bNAbs) against HIV-1 require understanding germli...
AbstractHIV-1 envelope glycoproteins (Env) and Env-based immunogens usually do not interact efficien...
The CD4 binding site (CD4bs) of the HIV-1 envelope glycoprotein is susceptible to multiple lineages ...
International audienceBroadly neutralizing antibodies (bnAbs) directed to the V2 apex of the HIV env...
SummaryBroadly neutralizing antibodies (bnAbs) directed to the V2 apex of the HIV envelope (Env) tri...
Understanding how broadly neutralizing antibodies (bnAbs) to HIV envelope (Env) develop during natur...
International audienceUnderstanding how broadly neutralizing antibodies (bnAbs) to HIV envelope (Env...
The CD4 binding site (CD4bs) of the HIV-1 envelope glycoprotein is susceptible to multiple lineages ...
SummaryBroadly neutralizing antibodies (bnAbs) against the N332 supersite of the HIV envelope (Env) ...
Worldwide, over 37 million people are currently infected with rapidly mutating human immunodeficienc...
Vaccine candidates for HIV-1 so far have not been able to elicit broadly neutralizing antibodies (bN...
Broadly neutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV)-1 are rare in nat...
Broadly neutralizing antibodies (bnAbs) against HIV are believed to be a critical component of the p...
Several human monoclonal antibodies (hmAbs) and antibody fragments, including the best characterized...
HIV-1 envelope glycoproteins (Env) and Env-based immunogens usually do not interact efficiently with...
Efforts to elicit broadly neutralizing antibodies (bNAbs) against HIV-1 require understanding germli...
AbstractHIV-1 envelope glycoproteins (Env) and Env-based immunogens usually do not interact efficien...
The CD4 binding site (CD4bs) of the HIV-1 envelope glycoprotein is susceptible to multiple lineages ...
International audienceBroadly neutralizing antibodies (bnAbs) directed to the V2 apex of the HIV env...
SummaryBroadly neutralizing antibodies (bnAbs) directed to the V2 apex of the HIV envelope (Env) tri...
Understanding how broadly neutralizing antibodies (bnAbs) to HIV envelope (Env) develop during natur...
International audienceUnderstanding how broadly neutralizing antibodies (bnAbs) to HIV envelope (Env...
The CD4 binding site (CD4bs) of the HIV-1 envelope glycoprotein is susceptible to multiple lineages ...
SummaryBroadly neutralizing antibodies (bnAbs) against the N332 supersite of the HIV envelope (Env) ...
Worldwide, over 37 million people are currently infected with rapidly mutating human immunodeficienc...